CClinicalTrials.gg
Sign In
RecruitingNCT06714214PRESSINGUpdated Dec 10, 2024

PREdiction of succeSSful weanING From Continuous Renal Replacement Theraphy: the Possible Role of Delta C-cistatin

An observational study in Acute Kidney Injury, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-10.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
152
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to know if, in patients with acute kidney injury, naive for renal injurie, admitted to different ICUs, the change in plasma concentration of c-cistatin, between initiation and discontinuation of CRRT, is a predictive finding to optimize the withdrawal time of renal support

02

Conditions studied

  • Acute Kidney Injury

Browse trials for

Keywords

  • C cistatin
  • acute kidney injury
  • CRRT
  • weaning
03

In context

Acute Kidney Injury

1,595 studies on the registry are indexed under Acute Kidney Injury; 371 are open to participants now.

This study's planned enrollment of 152 is close to the median of 150 across 773 observational studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 493 studies on the registry; 273 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will include all adult patients suffering from acute renal injury needing to CRRT, admitted to the enrolling centers starting from the approval of the Ethics Committee

Inclusion criteria

  • age ≥ 18 years;
  • diagnosis of acute kidney injury (defined according to KDIGO 2012 criteria)
  • need for support with CRRT according to the indications of the nephrologist consultants and Clinical Practice
  • Obtaining informed consent

Exclusion criteria

Exclusion Criteria:

  • CRRT already ongoing (in another department not participating in the study) at the time of transfer/admission to intensive care;
  • need for RRT (any type and modality) in the 14 days prior to enrolment;
  • diagnosis of AKD/CKD/ESRF on admission;
  • Discontinuation of CRRT under conditions that do not comply with the criteria established by the study;
  • Need for CRRT not associated with AKI condition (e.g. elimination of toxicants);
  • pregnant women;
  • presence of known thyreopathy
  • Continuous use of corticosteroids
  • patient with known neoplastic disease.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
152 participants (estimated)
Target follow-up
28 Days
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. the change in plasma concentration of c-cistatin between initiation and discontinuation of CRRT is a predictive finding in patients with acute kidney injury admitted to the ICU

    To verify whether the change in plasma concentration of c-cistatin between initiation and discontinuation of CRRT is a predictive finding in patients with acute kidney injury admitted to the ICU It is measured as (cistatin at weaning minus cistatin basal) divided by cistatine basal, in percentage

    Time frame: From enrlollment to the weaning from CRRT and 14 days after

07

Study locations

2 of 2 sites recruiting
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Anestesia e Terapia Intensiva nelle emergenze locali, regionali e nazionale e nella chirurgia addominale maggiore
    Bologna, 40138, Italy
    Recruiting
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna -Anestesiologia e terapia intensiva polivalente
    Bologna, 40138, Italy
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06714214
Lead sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Responsible party
Sponsor
First posted
Dec 3, 2024
Start date
Oct 1, 2024
Primary completion
Aug 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Dec 10, 2024

Study contacts

Francesco Marino, MD
Contact
francesco.marino@aosp.bo.it
3293842166
Francesco Marino, MD
principal investigator · IRCCS Azienda Ospedaliero-Universitaria di Bologna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Acute Kidney Injury→

Other studies from this sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Start the discussion